Results 101 to 110 of about 8,114 (214)

A Tutorial on the Development of a Physiologically Inspired PKRO Model for Monoclonal Antibodies

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Modeling and simulations are indispensable tools to describe pharmacokinetics (PK) and pharmacodynamics to support monoclonal antibody (mAb) development. The linear PK of mAbs is commonly described by a 2‐compartment PK model, while the nonlinear PK often observed at low doses is described by target mediated drug disposition (TMDD) models ...
Georgi I. Kapitanov, David Flowers, Diana H. Marcantonio, Timothy R. Lezon, Josh F. Apgar, Fei Hua   +5 more
wiley   +1 more source

Human FcRn can mediate the transport across intestinal mucosal barrier and prolong the half-life of rabbit IgG in vivo [PDF]

, 2015
Guangchang Pang, Yufang Wang, Junbo Xie, Chen Qing-sen, HU Zhi-he   +4 more
openalex   +1 more source

Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties

mAbs
Nipocalimab is a human immunoglobulin G (IgG)1 monoclonal antibody that binds to the neonatal Fc receptor (FcRn) with high specificity and high affinity at both neutral (extracellular) and acidic (intracellular) pH, resulting in the reduction of ...
Nilufer P. Seth, Rui Xu, Matthew DuPrie, Amit Choudhury, Samuel Sihapong, Steven Tyler, James Meador, William Avery, Edward Cochran, Thomas Daly, Julia Brown, Laura Rutitzky, Lynn Markowitz, Sujatha Kumar, Traymon Beavers, Sayak Bhattacharya, Hsin Chen, Viraj Parge, Karen Price, Yang Wang, Siddharth Sukumaran, Yvonne Pao, Katie Abouzahr, Fiona Elwood, Jay Duffner, Sucharita Roy, Pushpa Narayanaswami, Jonathan J. Hubbard, Leona E. Ling   +28 more
doaj   +1 more source

FcRn Expression on Placenta and Fetal Jejunum during Early, Mid-, and Late Gestation in Minipigs [PDF]

, 2015
Björn Jacobsen, Marilyn Hill, Lucie Reynaud, Adam Hey, Paul Barrow   +4 more
openalex   +1 more source

Enhanced Clearance of HIV‐1 Broadly Neutralizing Antibody VRC07‐523‐LS During Viremia: Influences on Trial Design and Analysis

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Broadly neutralizing antibodies (BNAb) are capable of neutralizing multiple HIV‐1 strains through the targeting of conserved epitopes. This study's objective was to quantify the pharmacokinetic (PK) parameters describing the distribution and elimination of the BNAb VRC07‐523‐LS in people with HIV (PWH), and to identify the influence of viral ...
Nicholas M. Smith, Brian M. Ho, Katharine J. Bar, Lucio Gama, Gabrielle Dziubla, Richard A. Koup, Michael Pensiero, Leonid Serebryannyy, Marina Caskey, Timothy J. Wilkin, Troy D. Wood, Gene D. Morse, Charles S. Venuto, Ray Cha, Qing Ma   +14 more
wiley   +1 more source

Targeting the neonatalFcreceptor (FcRn) to treat autoimmune diseases and maternal‐fetal immune cytopenias

, 2021
Sarah L. Wyckoff, Krystalyn E. Hudson
openalex   +2 more sources

Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitus

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1350-1358, February 2026.
Abstract Aims To evaluate treatment‐emergent antidrug antibodies (TE ADA) in once‐weekly basal insulin efsitora‐treated participants with type 1 and type 2 diabetes mellitus (T1DM and T2DM) from 5 phase 3 clinical trials and their potential impact on pharmacokinetics, efficacy and safety.
Yun Wang, Sihe Wang, Wei Wang, Xiaoqi Li, Jennifer Leohr, Vitoria Pires, Michelle L. Katz, Christopher J. Child, Robert J. Konrad   +8 more
wiley   +1 more source

Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn

mAbs
Monoclonal antibodies (mAbs) as therapeutics necessitate favorable pharmacokinetic properties, including extended serum half-life, achieved through pH-dependent binding to the neonatal Fc receptor (FcRn).
Johannes Reusch, Jan Terje Andersen, Ulrich Rant, Tilman Schlothauer   +3 more
doaj   +1 more source

Spotlight commentary—Insulin therapy: Future directions

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 351-353, February 2026.
Ana Deškin, Klara Cifrek, Lara Maria Stričak, Ana Hladnik, Jelena Osmanović Barilar   +4 more
wiley   +1 more source

1‐Year Clinical Outcome Post‐Myasthenic Crisis: A Multicenter Prospective Study in China

European Journal of Neurology, Volume 33, Issue 2, February 2026.
In this prospective cohort of 282 patients with myasthenic crisis (MC) episodes, all‐cause mortality was 15.16%. Among 247 patients who have completed 1‐year follow‐up, 79.76% achieved favorable outcomes with significant improvement in the MG‐activities of daily living (MG‐ADL) score.
Xiao Huan, Ran Chen, Lei Jin, Yuan Wang, Yafang Xu, Lei Yang, Caihua Xi, Jianming Zheng, Lijun Luo, Song Yang, Jianquan Shi, Yanping Liu, Zhe Ruan, Wanlong Wu, Wei Li, Yaoxian Yue, Yarong Li, Wenji Jia, Huahua Zhong, Chong Yan, Jie Song, Jianying Xi, Song Tan, Qilong Jiang, Zhangyu Zou, Chongbo Zhao, Sushan Luo, on behalf of the Chinese Myasthenia Gravis Collaborating Group (CMGCG), Yuzhou Guan, Yuwei Da, Huan Yang, Ting Chang, Yuge Wang, Bitao Bu, Hongyu Zhou, Chunsheng Yang, Hua Zhang, Hui Deng, Ruisheng Duan   +38 more
wiley   +1 more source